NO20051182L - Fremgangmater for a indusere T-celle-toleranse hos et vevs- eller organtransplantat - Google Patents

Fremgangmater for a indusere T-celle-toleranse hos et vevs- eller organtransplantat

Info

Publication number
NO20051182L
NO20051182L NO20051182A NO20051182A NO20051182L NO 20051182 L NO20051182 L NO 20051182L NO 20051182 A NO20051182 A NO 20051182A NO 20051182 A NO20051182 A NO 20051182A NO 20051182 L NO20051182 L NO 20051182L
Authority
NO
Norway
Prior art keywords
cell
tissue
antagonist
allogeneic
xenogenic
Prior art date
Application number
NO20051182A
Other languages
English (en)
Inventor
Randolph J Noelle
Fiona H Durie
David C Parker
Michael C Appel
John P Mordes
Aldo A Rossini
Nancy E Phillips
Dale L Greiner
Original Assignee
Dartmouth College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of NO20051182L publication Critical patent/NO20051182L/no
Application filed by Dartmouth College filed Critical Dartmouth College

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)

Abstract

Det beskrives fremgangsmåter for å indusere T-celletoleranse for et vevs- eller organtransplantat hos en transplantatmottaker. Fremgangsmåtene omfatter å administrere til en transplantatmottaker: 1) en allogeneisk eller xenogeneisk celle som uttrykker minst ett donorantigen og som har en ligand på celleoverflaten som vekselvirker med en receptor på overflaten av en mottaker T~celle som medierer berøringsavhengig hjelperutløsningsfunksjon og 2) en antagonist av receptoren, som hemmer vekselvirkning mellom liganden og receptoren. I en foretrukken utførelsesform er den allogeneiske eller xenogeneiske celle en B-celle, fortrinnsvis en hvilende Bcelle, og molekylet på overflaten av T-cellen som medierer berøringsavhengig hjelper-utløsningsfunksjon, er gp39. En foretrukken gp39-antagonist er et anti-gp39-antistoff. Den allogeneiske eller xenogeneiske celle og gp39-antagonisten administreres vanligvis til en transplantatmottaker før transplantasjonen av vevet eller organet. Fremgangsmåtene ifølge oppfinnelsen kan anvendes for å indusere Tcelletoleranse for transplantater så som lever, nyre, hjerte, lunge, hud, muskel, neuronalvev, mage og tarmer. Det beskrives også en fremgangsmåte ved behandling av diabetes, omfattende å administrere til en pasient allogeneiske eller xenogeneiske celler som uttrykker donorantigener, en gp39-antagonist og Langerhans øyer.
NO20051182A 1994-04-25 2005-03-04 Fremgangmater for a indusere T-celle-toleranse hos et vevs- eller organtransplantat NO20051182L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/234,987 US5683693A (en) 1994-04-25 1994-04-25 Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
PCT/US1995/004832 WO1995028957A2 (en) 1994-04-25 1995-04-25 Methods for inducing t cell tolerance to a tissue or organ graft

Publications (1)

Publication Number Publication Date
NO20051182L true NO20051182L (no) 1996-12-23

Family

ID=22883593

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19964440A NO319787B1 (no) 1994-04-25 1996-10-18 Anvendelse av allogenisk eller xenogenisk celle som vekselvirker med en gp39-antagonist ved fremstilling av et preparat til induksjon av T-celle-toleranse hos et vevs- eller organ-transplantat.
NO20051182A NO20051182L (no) 1994-04-25 2005-03-04 Fremgangmater for a indusere T-celle-toleranse hos et vevs- eller organtransplantat

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO19964440A NO319787B1 (no) 1994-04-25 1996-10-18 Anvendelse av allogenisk eller xenogenisk celle som vekselvirker med en gp39-antagonist ved fremstilling av et preparat til induksjon av T-celle-toleranse hos et vevs- eller organ-transplantat.

Country Status (34)

Country Link
US (4) US5683693A (no)
EP (2) EP1530973A3 (no)
JP (1) JP2974415B2 (no)
KR (1) KR100468330B1 (no)
CN (1) CN1134266C (no)
AP (1) AP764A (no)
AT (1) ATE288281T1 (no)
AU (1) AU710925B2 (no)
BG (1) BG62121B1 (no)
BR (1) BR9507509A (no)
CA (1) CA2188672A1 (no)
CZ (1) CZ291266B6 (no)
DE (1) DE69533984T2 (no)
DK (1) DK0757557T3 (no)
EE (1) EE03516B1 (no)
ES (1) ES2237757T3 (no)
FI (1) FI118792B (no)
GE (1) GEP20022648B (no)
HU (1) HU221752B1 (no)
IS (1) IS2118B (no)
LT (1) LT4309B (no)
LV (1) LV11785B (no)
MD (1) MD1444B2 (no)
NO (2) NO319787B1 (no)
NZ (1) NZ284905A (no)
OA (1) OA10591A (no)
PL (1) PL180031B1 (no)
PT (1) PT757557E (no)
RO (1) RO114743B1 (no)
RU (1) RU2169009C2 (no)
SI (1) SI9520057A (no)
SK (1) SK136996A3 (no)
UA (1) UA44892C2 (no)
WO (1) WO1995028957A2 (no)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US7070777B1 (en) * 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US6472510B1 (en) 1992-02-14 2002-10-29 Bristol-Myers Squibb Company CD40 receptor ligands
ZA946765B (en) * 1993-09-02 1996-02-15 Dartmouth College Methods of prolonged suppression of humoral immunity
CN1127351C (zh) * 1993-09-02 2003-11-12 达特茅斯学院理事 诱导抗原特异性ｔ细胞耐受的方法
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US6440418B1 (en) * 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
ATE219376T1 (de) * 1996-03-20 2002-07-15 Bristol Myers Squibb Co Verfahren zur inhibierung der immunreaktion durch blockierung der gp39/cd40 und ctla4/cd28/b7 routen und zusammensetzung zu deren verwendung
CA2277223A1 (en) * 1997-01-10 1998-07-16 Biogen, Inc. Methods of therapeutic administration of anti-cd40l compounds
EP2030614A1 (en) * 1997-02-27 2009-03-04 Novartis AG Pharmaceutical Composition comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol and a lecithin
EA002550B1 (ru) * 1997-06-20 2002-06-27 Байоджен, Инк. Лечение посредством блокады cd154 при трансплантации ткани панкреатических островков
EP1754490A3 (en) * 1997-06-20 2010-01-20 Biogen Idec MA Inc. CD 154 blockage therapy for pancreatic islet tissue transplantation in primates
US6051228A (en) * 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
US20050031611A1 (en) * 1998-05-08 2005-02-10 Beth Israel Deaconess Medical Center Transplant tolerance by costimulation blockade and T-cell activation-induced apoptosis
ATE309808T1 (de) * 1998-07-30 2005-12-15 Univ Minnesota Ex vivo behandlung von allogenen und xenogenen t- zellen mit gp39-antagonisten
US20020199218A1 (en) * 1999-08-19 2002-12-26 Daphne Goring Proline-rich extensin-like receptor kinases
RU2162297C1 (ru) * 1999-11-25 2001-01-27 Камакин Владислав Владимирович Способ индивидуального подбора оптимального питания человека
WO2001079555A2 (en) 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
EP1284747A2 (en) 2000-05-12 2003-02-26 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
WO2001093908A1 (en) * 2000-06-02 2001-12-13 Regents Of The University Of Minnesota Immunotherapeutic method to prevent islet cell rejection
AU7522401A (en) * 2000-06-06 2001-12-17 Idec Pharma Corp Non-agonistic antibodies to human gp39, compositions containing, and therapeuticuse thereof
CA2630062C (en) 2000-07-03 2014-10-14 Bristol-Myers Squibb Company Methods for treating graft versus host disease and immune disorders associated with rejection using a soluble ctla4 molecule
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
CA2364983A1 (en) * 2000-12-13 2002-06-13 John R. Coleman Nucleic acid molecules and polypeptides for catabolism of abscisic acid
WO2002078743A1 (en) * 2001-02-16 2002-10-10 University Of Rochester Compositions and methods for reducing tranfusion reactions
US7556807B2 (en) 2001-02-20 2009-07-07 Kane Biotech, Inc. Signal peptides, nucleic acid molecules and methods for treatment of caries
US7597895B2 (en) * 2001-02-20 2009-10-06 The Governing Council Of The University Of Toronto Signal peptides, nucleic acid molecules and methods for treatment of caries
ATE390931T1 (de) 2001-05-23 2008-04-15 Bristol Myers Squibb Co Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4- mutationsmolekülen
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
CN1678634A (zh) * 2002-06-28 2005-10-05 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
DE10231655A1 (de) * 2002-07-12 2004-02-26 Blasticon Biotechnologische Forschung Gmbh Transplantat-Akzeptanz induzierende Zellen monozytären Ursprungs, sowie deren Herstellung und Verwendung
EP1460088A1 (en) * 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
US20070041971A1 (en) * 2003-07-07 2007-02-22 Wagner David H Methods for predicting development of auto-immune diseases and treatment of same
EP1707627B1 (en) * 2003-12-25 2012-11-14 Kyowa Hakko Kirin Co., Ltd. Antagonistic anti-CD40 antibody mutant
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
EP1795587A1 (en) * 2005-12-07 2007-06-13 Schuler, Gerold, Prof. Dr. Method for the direct culture of dendritic cells without a preceding centrifugation step
BRPI0708424A2 (pt) * 2006-03-02 2011-05-31 Alexion Pharma Inc prolongamento da sobreviência de uma aloenxerto por inibição da atividade do complemento
FR2934140B1 (fr) * 2008-07-25 2010-09-03 Seb Sa Couvercle d'appareil electromenager de cuisson comportant un sous-ensemble de filtration
JP5836940B2 (ja) 2009-06-26 2015-12-24 ソリシメド・バイオファーマ・インコーポレーテッド ソリシジン由来ペプチドならびにｔｒｐｖ−６がんの検出および薬剤送達のための方法
WO2013013708A1 (en) 2011-07-26 2013-01-31 Fundació Institut D'investigació Biomèdica De Bellvitge Treatment of acute rejection in renal transplant
WO2016094679A1 (en) 2014-12-10 2016-06-16 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
RU2580640C1 (ru) * 2014-12-25 2016-04-10 Федеральное государственное бюджетное учреждение "Федеральный научный центр трансплантологии и искусственных органов имени академика В.И. Шумакова" Министерства здравоохранения Российской Федерации Способ профилактики гуморального отторжения при аво-несовместимой трансплантации печени детям раннего возраста
RU2688172C1 (ru) * 2018-04-05 2019-05-20 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ профилактики отторжения трансплантата трупной почки

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4415553A (en) * 1973-08-06 1983-11-15 Dso "Pharmachim" Compositions, processes for their preparation and method for treatment of neoplasms
PT89107A (pt) * 1987-11-30 1989-11-30 Idec Pharma Corp Metodo e meios para a seleccao de anticorpos anti-idiotipos e seu uso para o diagnostico, monitorizacao, tratamento e/ou prevencao de doencas cancerosas, da autoimunidade ou infecciosas
EP0408859B1 (en) * 1989-05-23 1995-08-09 Otsuka Pharmaceutical Co., Ltd. Monoclonal antibodies to activated endothelial cells
US5690933A (en) * 1989-05-31 1997-11-25 Glaxo Wellcome Inc. Monoclonal antibodies for inducing tolerance
US5283058A (en) * 1990-08-30 1994-02-01 The General Hospital Corporation Methods for inhibiting rejection of transplanted tissue
BR9206649A (pt) * 1991-10-18 1995-10-24 Cantab Pharma Res Processo para o tratamento in vitro de um rim antes do transplante em um receptor humano
DK0897983T3 (da) * 1991-10-25 2003-08-11 Immunex Corp Antistoffer mod CD40-L
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
CA2089229C (en) * 1992-02-14 2010-04-13 Alejandro A. Aruffo Cd40cr receptor and ligands therefor
WO1994004570A1 (en) * 1992-08-21 1994-03-03 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
US5597563A (en) * 1992-09-04 1997-01-28 Beschorner; William E. Method induction of antigen-specific immune tolerance
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
CA2109398A1 (en) * 1992-10-30 1994-05-01 Alejandro A. Aruffo Extracellular matrix receptor ligands that modulate leukocyte function
ZA946765B (en) * 1993-09-02 1996-02-15 Dartmouth College Methods of prolonged suppression of humoral immunity
US5869049A (en) * 1993-09-02 1999-02-09 Trustees Of Dartmouth College Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
CN1127351C (zh) * 1993-09-02 2003-11-12 达特茅斯学院理事 诱导抗原特异性ｔ细胞耐受的方法
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40

Also Published As

Publication number Publication date
IS4378A (is) 1996-10-22
DE69533984D1 (de) 2005-03-10
BG100991A (en) 1998-01-30
KR100468330B1 (ko) 2005-12-30
DE69533984T2 (de) 2006-04-27
CN1134266C (zh) 2004-01-14
NO964440L (no) 1996-12-23
BR9507509A (pt) 1997-02-02
LT4309B (lt) 1998-03-25
LV11785B (en) 1998-02-20
BG62121B1 (bg) 1999-03-31
CZ312596A3 (en) 1997-03-12
SI9520057A (sl) 1998-06-30
EE03516B1 (et) 2001-10-15
US6375950B1 (en) 2002-04-23
FI964272A0 (fi) 1996-10-23
AU710925B2 (en) 1999-09-30
PT757557E (pt) 2005-05-31
EP1530973A2 (en) 2005-05-18
PL180031B1 (pl) 2000-12-29
GEP20022648B (en) 2002-03-25
JP2974415B2 (ja) 1999-11-10
SK136996A3 (en) 1999-01-11
RO114743B1 (ro) 1999-07-30
MD970009A (en) 1999-01-31
US5902585A (en) 1999-05-11
AP764A (en) 1999-09-16
US5683693A (en) 1997-11-04
OA10591A (en) 2002-07-15
WO1995028957A2 (en) 1995-11-02
LT96165A (en) 1997-11-25
NO964440D0 (no) 1996-10-18
EP0757557A1 (en) 1997-02-12
IS2118B (is) 2006-06-15
US7501124B2 (en) 2009-03-10
CZ291266B6 (cs) 2003-01-15
AU2358595A (en) 1995-11-16
ES2237757T3 (es) 2005-08-01
HU9602924D0 (en) 1996-12-30
UA44892C2 (uk) 2002-03-15
EP1530973A3 (en) 2006-12-27
CA2188672A1 (en) 1995-11-02
DK0757557T3 (da) 2005-05-23
MD1444B2 (ro) 2000-04-30
FI118792B (fi) 2008-03-31
WO1995028957A3 (en) 1995-11-23
EE9600162A (et) 1997-06-16
ATE288281T1 (de) 2005-02-15
CN1150760A (zh) 1997-05-28
EP0757557B1 (en) 2005-02-02
LV11785A (lv) 1997-06-20
RU2169009C2 (ru) 2001-06-20
FI964272A7 (fi) 1996-12-19
HU221752B1 (hu) 2002-12-28
NO319787B1 (no) 2005-09-12
JPH09512271A (ja) 1997-12-09
US20050152897A1 (en) 2005-07-14
NZ284905A (en) 2004-10-29
PL317022A1 (en) 1997-03-03
AP9600906A0 (en) 1997-01-31
HUT76091A (en) 1997-06-30

Similar Documents

Publication Publication Date Title
EP1530973A3 (en) Methods for inducing T cell tolerance to a tissue or organ graft
Krieglstein et al. Role of appendix and spleen in experimental colitis
Trainin et al. Studies on some physicochemical properties of a thymus humoral factor conferring immunocompetence on lymphoid cells
Madsen et al. TRANSPLANTATION TOLERANCE PREVENTS CARDIAC ALLOGRAFT VASCULOPATHY IN MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I-DISPARATE MINIATURE SWINE1
Höpken et al. The chemokine receptor CCR7 controls lymph node‐dependent cytotoxic T cell priming in alloimmune responses
RU96122475A (ru) Способы индуцирования т-клеточной толерантности к тканевому или органному трансплантанту
Vidic-Dankovic et al. Leflunomide prevents the development of experimentally induced myasthenia gravis
Jeffery et al. Comparison of pulmonary vascular function and structure in early and established hypoxic pulmonary hypertension in rats
DE69935603T2 (de) Inhibitoren von autoantikörpern
Jaffe et al. Multivisceral intestinal transplantation: surgical pathology
Volpé et al. The use of the severe combined immunodeficient mouse and the athymic" nude" mouse as models for the study of human autoimmune thyroid disease
DE69527640T2 (de) Zusammensetzungen die gemischte transferrine als wirkstoff für induktion von immunotoleranz gegen antigen enthalten
Kelly et al. Immunoregulation in experimental interstitial nephritis: immunization with renal tubular antigen in incomplete Freund's adjuvant induces major histocompatibility complex-restricted, OX8+ suppressor T cells which are antigen-specific and inhibit the expression of disease.
Rao et al. The two-way paradigm of transplantation immunology
Konturek GASTRIC SECRETION-FROM PAVLOV'S NERVISM TO POPIELSKI'S
Schirrmacher et al. Cytotoxic Immune Cells with Specificity for Defined Soluble Antigens: V. Interaction of Antibody with the Cytotoxic Effector Cells in Immune or Non-Immune Mouse Spleen Cells
AOKI et al. Involvement of vasoactive intestinal peptide (VIP) as a humoral mediator of penile erectile function in the dog
de Medinaceli et al. Posttraumatic autoimmune reaction in peripheral nerve: effect of a single injury
Blom et al. TOLERANCE INDUCTION BY INTRATHYMIC INOCULATION PREVENTS CHRONIC RENAL ALLOGRAFT REJECTION1, 2
Kakinuma et al. Strain differences in lung granuloma formation in response to a BCG cell-wall vaccine in mice. Failure of antigen presentation by low-responder macrophages
Babcock et al. Suppression of cell-mediated immune responses by dextran sulphate
Zhong et al. Long-term limb allograft survival using a short course of anti-CD45RB monoclonal antibody, LF 15-0195, and rapamycin in a mouse model
JPH06298654A (ja) 抗原特異的免疫抑制剤
Nusair et al. Simultaneous donor marrow cell transplantation with reduced intensity conditioning prevents tracheal allograft obliteration in a bronchiolitis obliterans murine model
Markmann et al. Prevention of recurrent diabetes in BB rats after islet transplantation by monoclonal antibody therapy

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application